Merck: Keytruda approved in Japan for three new indications
(CercleFinance.com) - Merck said that its Keytruda immunotherapy has received new approvals from Japanese health regulators in advanced renal cell carcinoma and head and neck cancer.
The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has approved Keytruda, in combination with Pfizer's Inlyta, for the first-line treatment of patients with radically unresectable or metastatic renal cell carcinoma.
Japanese regulators also approved Keytruda, in combination with chemotherapy, for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer, and for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer, Merck said.
Drugs for these aggressive forms of cancer have historically had poor outcomes.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has approved Keytruda, in combination with Pfizer's Inlyta, for the first-line treatment of patients with radically unresectable or metastatic renal cell carcinoma.
Japanese regulators also approved Keytruda, in combination with chemotherapy, for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer, and for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer, Merck said.
Drugs for these aggressive forms of cancer have historically had poor outcomes.
Copyright (c) 2019 CercleFinance.com. All rights reserved.